Cue Biopharma, INC. (CUE) — SEC Filings

Overview

Cue Biopharma, INC. (CUE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 22, 2026: On April 22, 2026, Cue Biopharma, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws. This filing indicates potential changes to the company's governance or operational structure, as outlined in Item 5.03.

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 31 neutral, 1 mixed. The dominant filing sentiment for Cue Biopharma, INC. is neutral.

Filing Type Overview

Cue Biopharma, INC. (CUE) has filed 19 8-K, 1 EFFECT, 6 10-Q, 2 DEFA14A, 3 DEF 14A, 2 10-K, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (36)

• Cue Biopharma Files 8-K on Bylaw Amendments — 8-K · Apr 22, 2026 Risk: medium
  On April 22, 2026, Cue Biopharma, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws. This filing indicates potential chan
• Cue Biopharma Files 8-K: Other Events — 8-K · Apr 7, 2026 Risk: low
  On April 1, 2026, Cue Biopharma, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant business
• EFFECT Filing — EFFECT · Apr 1, 2026
• Cue Biopharma Files 8-K: Material Agreement, Other Events — 8-K · Dec 19, 2025 Risk: medium
  On December 19, 2025, Cue Biopharma, Inc. filed an 8-K report. The filing indicates a material definitive agreement was entered into, and also reports other eve
• 8-K Filing — 8-K · Nov 24, 2025
• Cue Biopharma Announces Board Changes and Officer Compensation Updates — 8-K · Nov 20, 2025 Risk: medium
  On November 17, 2025, Cue Biopharma, Inc. reported a change in its board of directors, with the election of new directors and the departure of existing ones. Th
• Cue Biopharma Narrows Losses, Boosts Cash with ImmunoScape Deal — 10-Q · Nov 12, 2025 Risk: high
  Cue Biopharma, Inc. reported a net loss of $7.448 million for the three months ended September 30, 2025, an improvement from a net loss of $8.660 million in the
• Cue Biopharma Files 8-K: Material Agreement, Financials — 8-K · Nov 6, 2025 Risk: medium
  On November 6, 2025, Cue Biopharma, Inc. filed an 8-K report. The filing indicates a material definitive agreement was entered into, and also includes Regulatio
• Cue Biopharma Announces Board and Officer Changes — 8-K · Sep 29, 2025 Risk: medium
  Cue Biopharma, Inc. announced on September 26, 2025, changes in its board and officer composition. The company filed an 8-K report detailing the departure of di
• Cue Biopharma Narrows Q2 Loss Amidst Zero Revenue — 10-Q · Aug 12, 2025 Risk: high
  Cue Biopharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commercial
• Cue Biopharma Enters Material Definitive Agreement — 8-K · Jul 1, 2025 Risk: medium
  On June 30, 2025, Cue Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Imagen Biopharma, Inc., is incorporated in De
• Cue Biopharma Reports Director/Officer Changes & Corporate Updates — 8-K · Jun 10, 2025 Risk: medium
  Cue Biopharma, Inc. filed an 8-K on June 10, 2025, reporting several key events as of June 4, 2025. These include the departure of directors or certain officers
• Cue Biopharma Files Proxy Materials — DEFA14A · May 27, 2025 Risk: low
  Cue Biopharma, Inc. filed a Definitive Additional Materials proxy statement on May 27, 2025. This filing is related to the company's proxy materials and does no
• Cue Biopharma Files Q1 2025 10-Q, Cites Warrant Activity — 10-Q · May 12, 2025 Risk: medium
  Cue Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Imagen Biopharma, Inc., is in the pharmaceutical preparations ind
• Cue Biopharma Executive Compensation Details Released — DEF 14A · Apr 25, 2025 Risk: low
  Cue Biopharma, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes inform
• Cue Biopharma Files 8-K on Material Agreement — 8-K · Apr 15, 2025 Risk: medium
  On April 14, 2025, Cue Biopharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations and financial
• Cue Biopharma Enters Material Definitive Agreement — 8-K · Apr 14, 2025 Risk: medium
  On April 10, 2025, Cue Biopharma, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its count
• 10-K Filing — 10-K · Mar 31, 2025
• Cue Biopharma Announces Board and Executive Changes — 8-K · Mar 12, 2025 Risk: medium
  Cue Biopharma, Inc. announced on March 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of
• Cue Biopharma Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Cue Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operati
• Cue Biopharma Files 8-K on Shareholder Votes and Financials — 8-K · Oct 8, 2024 Risk: low
  On October 8, 2024, Cue Biopharma, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders and a
• Cue Biopharma Enters Material Definitive Agreement — 8-K · Oct 4, 2024 Risk: medium
  On October 2, 2024, Cue Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Imagen Biopharma, Inc., is incorporated in
• Cue Biopharma Enters Material Definitive Agreement — 8-K · Sep 27, 2024 Risk: medium
  On September 26, 2024, Cue Biopharma, Inc. entered into a material definitive agreement. The filing also notes other events and includes financial statements an
• Cue Biopharma Files Definitive Proxy Statement — DEF 14A · Sep 10, 2024 Risk: low
  Cue Biopharma, Inc. filed its definitive proxy statement (DEF 14A) on September 10, 2024, for its annual meeting of stockholders. The filing provides details re
• Cue Biopharma Files 8-K on Executive and Director Changes — 8-K · Sep 3, 2024 Risk: medium
  On August 28, 2024, Cue Biopharma, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing includes information on the el
• Cue Biopharma Faces Nasdaq Delisting — 8-K · Aug 16, 2024 Risk: high
  Cue Biopharma, Inc. filed an 8-K on August 15, 2024, to report its failure to meet the minimum bid price requirement for continued listing on the Nasdaq Capital
• Cue Biopharma Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Cue Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operatio
• Cue Biopharma Appoints New CMO, Adds Director — 8-K · Jul 25, 2024 Risk: medium
  On July 24, 2024, Cue Biopharma, Inc. announced the appointment of Dr. Anjana Shah as Chief Medical Officer and the election of Ms. Jennifer L. Morgan to its Bo
• Cue Biopharma Files 8-K on Director/Officer Changes — 8-K · Jun 7, 2024 Risk: medium
  On June 5, 2024, Cue Biopharma, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on
• Cue Biopharma Files Proxy Materials — DEFA14A · May 24, 2024 Risk: low
  Cue Biopharma, Inc. filed a Definitive Additional Materials (DEFA14A) on May 24, 2024. This filing is related to proxy materials, indicating a shareholder meeti
• Cue Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Cue Biopharma, Inc. (CUE) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Cue Biopharma, Inc. filed a 10-Q report for the period ending March 31, 2
• Cue Biopharma, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk: low
  Cue Biopharma, Inc. (CUE) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Cue Biopharma, Inc. will hold its 2024 Annual Meeting of Stockholder
• Cue Biopharma Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  Cue Biopharma, Inc. (CUE) filed a Annual Report (10-K) with the SEC on March 28, 2024. Cue Biopharma, Inc. filed its 2023 Form 10-K on March 28, 2024. The filin
• SC 13G Filing — SC 13G · Mar 11, 2024
• BlackRock Discloses 5.1% Stake in Cue Biopharma — SC 13G · Feb 7, 2024
  BlackRock Inc., a major investment firm, reported on February 7, 2024, that it holds a significant stake in Cue Biopharma Inc. (NASDAQ: CUE). As of January 31,
• BlackRock Discloses Passive Stake in Cue Biopharma — SC 13G · Jan 31, 2024
  BlackRock Inc., a major investment firm, reported on January 31, 2024, that it holds a significant stake in Cue Biopharma, Inc. as of December 31, 2023. This fi

Risk Profile

Risk Assessment: Of CUE's 30 recent filings, 3 were flagged as high-risk, 20 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Cue Biopharma, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $2.149M
• Net Income: -$7.448M
• EPS: N/A
• Debt-to-Equity: 1.39
• Cash Position: $11.701M
• Operating Margin: N/A
• Total Assets: $31.644M
• Total Debt: $18.398M

Key Executives

• Dr. Anjana Shah
• Ms. Jennifer L. Morgan

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory oversight. Companies like Cue Biopharma compete by developing innovative therapies, often relying on strategic partnerships and collaborations to fund development and access expertise. The sector is driven by scientific advancements, patent protection, and the potential for substantial returns upon successful drug commercialization.

Top Tags

material-agreement (5) · corporate-governance (4) · financials (4) · 10-Q (4) · biopharma (4) · executive-compensation (3) · Biotechnology (3) · management-change (3) · corporate-action (3) · Cue Biopharma (3)

Key Numbers

• iXBRL 8-K Size: 85639 — Size of the interactive data filing.
• EX-3.1 Size: 26931 — Size of the exhibit containing amendments.
• Net loss for Q3 2025: $7.448M — Improved from $8.660M in Q3 2024
• Net loss for nine months ended Sept 30, 2025: $28.187M — Improved from $31.178M in the same period of 2024
• Collaboration revenue for Q3 2025: $2.149M — Decreased from $3.336M in Q3 2024
• Research and development expenses for Q3 2025: $4.754M — Significantly decreased from $9.381M in Q3 2024
• Cash and cash equivalents as of Sept 30, 2025: $11.701M — Decreased from $22.459M at Dec 31, 2024
• Upfront payments from ImmunoScape agreement: $15.0M — Includes $5.0M received and $5.0M expected in Q4 2025
• Common shares outstanding as of Sept 30, 2025: 77,781,743 — Increased from 61,819,101 at Dec 31, 2024 due to equity offerings
• Net cash used in operating activities for nine months ended Sept 30, 2025: $20.611M — Reduced from $27.301M in the same period of 2024
• SEC File Number: 001-38327 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 47-3324577 — Tax identification number for the company.
• Revenue: $0 — for Q2 2025 and six months ended June 30, 2025, indicating pre-commercial stage
• Net Loss: $20.5M — for Q2 2025, a decrease from $22.1M in Q2 2024
• Research and Development Expense: $16.5M — for Q2 2025, down from $18.1M in Q2 2024

Frequently Asked Questions